Evidence map›Paper›PMID 32425806›Full record

ArticleFrontiers in physiology2020

Analysis of Cardiac Amyloidosis Progression Using Model-Based Markers.

Wenguang Li, Alan Lazarus, Hao Gao, Ana Martinez-Naharro, Marianna Fontana, Philip Hawkins, Swethajit Biswas, Robert Janiczek, Jennifer Cox, Colin Berry and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Wenguang LiSchool of Mathematics and Statistics, University of Glasgow, Glasgow, United Kingdom.
Alan LazarusSchool of Mathematics and Statistics, University of Glasgow, Glasgow, United Kingdom.
Hao GaoSchool of Mathematics and Statistics, University of Glasgow, Glasgow, United Kingdom.
Ana Martinez-NaharroCentre for Amyloidosis and Acute Phase Proteins, University College London, London, United Kingdom.
Marianna FontanaCentre for Amyloidosis and Acute Phase Proteins, University College London, London, United Kingdom.
Philip HawkinsCentre for Amyloidosis and Acute Phase Proteins, University College London, London, United Kingdom.
Swethajit BiswasGlaxoSmithKline plc, Stevenage, United Kingdom.
Robert JaniczekGlaxoSmithKline plc, Stevenage, United Kingdom.
Jennifer CoxGlaxoSmithKline plc, Stevenage, United Kingdom.
Colin BerryBritish Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
Dirk HusmeierSchool of Mathematics and Statistics, University of Glasgow, Glasgow, United Kingdom.
Xiaoyu LuoSchool of Mathematics and Statistics, University of Glasgow, Glasgow, United Kingdom.
University of Glasgow · GBUniversity College London · GBGlaxoSmithKline (United Kingdom) · GBAge UK · GBBritish Heart Foundation · GB

Funding

British Heart Foundation FS/18/21/33447British Heart Foundation PG/11/2/28474British Heart Foundation PG/14/64/31043
6 · The paper itself

Abstract

Deposition of amyloid in the heart can lead to cardiac dilation and impair its pumping ability. This ultimately leads to heart failure with worsening symptoms of breathlessness and fatigue due to the progressive loss of elasticity of the myocardium. Biomarkers linked to the clinical deterioration can be crucial in developing effective treatments. However, to date the progression of cardiac amyloidosis is poorly characterized. There is an urgent need to identify key predictors for disease progression and cardiac tissue function. In this proof of concept study, we estimate a group of new markers based on mathematical models of the left ventricle derived from routine clinical magnetic resonance imaging and follow-up scans from the National Amyloidosis Center at the Royal Free in London. Using mechanical modeling and statistical classification, we show that it is possible to predict disease progression. Our predictions agree with clinical assessments in a double-blind test in six out of the seven sample cases studied. Importantly, we find that multiple factors need to be used in the classification, which includes mechanical, geometrical and shape features. No single marker can yield reliable prediction given the complexity of the growth and remodeling process of diseased hearts undergoing high-dimensional shape changes. Our approach is promising in terms of clinical translation but the results presented should be interpreted with caution due to the small sample size.

Indexed as

cardiac amyloidosisclassificationleft ventriclemodel-based markersMRIshape analysisstrain and stress

Identifiers

PMID32425806
PMCPMC7203577
OpenAlexW3019063807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.